ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08599
0,05%
Bitcoin
70.093,18
-0,05%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Rxi Pharmaceuticals Corp. (MM) (RXII)

  7. Rxi Pharmaceuticals Corp. (MM) (RXII) News

RXII

RXI Pharmaceuticals Corporation (RXII)

Rxi Pharmaceuticals Corp. (MM)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RXII
DatumZeitQuelleÜberschriftSymbolFirma
15/02/201913h15PR Newswire (US)Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/12/201815h35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/11/201815h30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
19/11/201823h52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201813h12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201813h10PR Newswire (US)RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201813h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
13/11/201823h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
13/11/201815h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
07/11/201813h05PR Newswire (US)RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell T...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
06/11/201813h05PR Newswire (US)RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
29/10/201814h28Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
15/10/201815h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/10/201820h00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
05/10/201823h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
03/10/201822h31PR Newswire (US)RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201823h32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201823h30Edgar (US Regulatory)Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201818h42Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201812h39Edgar (US Regulatory)Registration of Additional Securities (up to 20%) (s-1mef)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201812h36Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201812h10PR Newswire (US)RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/09/201812h14Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/09/201814h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/09/201814h00PR Newswire (US)RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intra...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/09/201823h48Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/09/201823h48Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
04/09/201813h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
31/08/201823h32Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/08/201815h15PR Newswire (US)RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
 Showing the most relevant articles for your search:NASDAQ:RXII

Kürzlich von Ihnen besucht

CCOM
US100
US Tech 100
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
FX
EURUSD
Euro vs US Dollar
TG
RHM
Rheinmetall
CCOM
US500
US 500
CCOM
SILVER
SILVER
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
NYSE
JPM
JP Morgan Chase
DBI
TDXP
Tec DAX
TG
DTE
Deutsche Telekom
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten